Fig. 4
From: Tumour inhibitory activity on pancreatic cancer by bispecific nanobody targeting PD-L1 and CXCR4
Therapeutic effect of the bispecific nanobody in vivo. a Tumour growth curve of the AsPC-1 mouse xenograft model in the different treatment groups (N = 5/group). Tumour volumes were measured by Vernier callipers every 3 days. A total of 2 × 106 AsPC-1 cells were injected into the right flank of each mouse, and 2 × 106 unstimulated PBMCs were injected into the caudal vein after the tumours reached approximately 100 mm3 in size. The mice were administered with PBS, 3 mg/kg atezolizumab and the two nanobodies (0.3 mg/kg Nb CXCR4 and 0.3 mg/kg Nb PD-L1) or 0.3 mg/kg BsNb PX4. b All tumour masses were photographed. c Weight of the tumour masses. d Tumour sections were stained with anti-CD31, anti-αSMA and anti-His-tag mAbs. (a-c) The data are presented as the mean ± S.D. (n = 5); *P < 0.05, ** P < 0.01, ***P < 0.001. “Combined Nbs” represents the co-treatment group of Nb CXCR4 and Nb PD-L1